Holen Sie sich die Stockscreener-App
1.975
2.07%
-0.035
Schlusskurs vom Vortag:
$2.01
Offen:
$2.01
24-Stunden-Volumen:
621.57K
Relative Volume:
0.39
Marktkapitalisierung:
$140.64M
Einnahmen:
$391.70K
Nettoeinkommen (Verlust:
$-52.34M
KGV:
-2.6333
EPS:
-0.75
Netto-Cashflow:
$-45.92M
1W Leistung:
+3.05%
1M Leistung:
+38.61%
6M Leistung:
+56.21%
1J Leistung:
+347.34%
1-Tages-Spanne:
$1.96
$2.10
1-Wochen-Bereich:
$1.8223
$2.3701
52-Wochen-Spanne:
$0.2425
$2.3701
Ovid Therapeutics Inc Stock (OVID) Company Profile
Firmenname
Ovid Therapeutics Inc
Sektor
Branche
Telefon
212-776-4381
Adresse
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
1.975 | 143.14M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.38 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.36 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
704.47 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.33 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.43 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-11 | Eingeleitet | Roth Capital | Buy |
| 2025-11-17 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-09 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-08 | Fortgesetzt | B. Riley Securities | Buy |
| 2024-06-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-04-30 | Eingeleitet | B. Riley Securities | Buy |
| 2024-04-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-05 | Eingeleitet | Wedbush | Outperform |
| 2023-12-21 | Eingeleitet | BTIG Research | Buy |
| 2023-10-13 | Eingeleitet | Oppenheimer | Outperform |
| 2021-04-20 | Herabstufung | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-04-20 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Ovid Therapeutics Inc Aktie (OVID) Neueste Nachrichten
Aug Sectors: Will Ovid Therapeutics Inc announce a stock splitPortfolio Growth Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Market Trends: Does Ovid Therapeutics Inc have declining or rising EPS2026 Setups & Accurate Technical Buy Alerts - baoquankhu1.vn
Ovid Therapeutics Gains Attention Amidst Market Fluctuations - StocksToTrade
OVID Therapeutics Faces Market Volatility Amid Recent Developments - timothysykes.com
Shorts Report: Is Ovid Therapeutics Inc being accumulated by smart moneyJuly 2025 Action & Weekly Sector Rotation Insights - baoquankhu1.vn
Support Test: Is Ovid Therapeutics Inc being accumulated by smart moneyIPO Watch & High Return Trade Guides - baoquankhu1.vn
Ovid Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
OVID Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
OVID: OV329 and OV4071 advance in CNS disorders, with major clinical data expected within 18 months - TradingView
OVID: Two CNS programs—OV329 for epilepsy and OV4071 for psychosis—advance with pivotal data ahead - TradingView
Ovid Therapeutics (OVID) to Release Quarterly Earnings on Tuesday - MarketBeat
OVID PE Ratio & Valuation, Is OVID Overvalued - Intellectia AI
Tax-cover sale as Ovid Therapeutics (OVID) CEO granted 1,435,000 options - Stock Titan
Ovid Therapeutics (NASDAQ: OVID) director awarded 65,000 stock options - Stock Titan
Ovid Therapeutics (NASDAQ: OVID) awards 957,000 stock options to director Jeremy Levin - Stock Titan
Ovid Therapeutics (OVID) director granted 65,000-share option award - Stock Titan
Ovid Therapeutics (OVID) director awarded 65,000 stock options vesting in 2027 - Stock Titan
Ovid Therapeutics (OVID) director awarded 65,000 stock options - Stock Titan
Ovid (NASDAQ: OVID) CBFO gets major equity awards, small tax sale - Stock Titan
Aug Final Week: Does Ovid Therapeutics Inc have declining or rising EPSJuly 2025 Intraday Action & Stepwise Trade Signal Implementation - baoquankhu1.vn
Ovid Therapeutics (NASDAQ:OVID) Given Average Recommendation of "Buy" by Analysts - MarketBeat
OVID Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Ovid Therapeutics (NASDAQ:OVID) Trading 7.3% HigherShould You Buy? - MarketBeat
Ovid Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Insider Sell: Is Ovid Therapeutics Inc still a buy after recent gainsTrade Risk Report & Stepwise Trade Execution Plans - baoquankhu1.vn
Aug Spikes: Is Ovid Therapeutics Inc still a buy after recent gainsMarket Activity Summary & Stepwise Trade Signal Guides - baoquankhu1.vn
ADAR1 reports 6.9% stake in Ovid Therapeutics (NASDAQ: OVID) - Stock Titan
Ovid Therapeutics (OVID) Sees 42.98% Increase Over the Past Week: Key Insights to Consider - Intellectia AI
ZCMD, ABCL, VOR, IXHL, OVID, BFRG Surge in After-Hours Trading Due to Clinical Progress and Recent Developments - Intellectia AI
Is Ovid Therapeutics Inc. being accumulated by smart moneyPortfolio Performance Summary & Daily Profit Focused Stock Screening - mfd.ru
Is Ovid Therapeutics (OVID) one of the best fast growing penny stocks to buy according to analysts? - MSN
Will Ovid Therapeutics Inc. announce a stock splitOptions Play & Safe Entry Point Alerts - mfd.ru
Ovid takes another big swing in neuroscience under a new CEO - Pharma Voice
Is Ovid Therapeutics Inc. (1OT) stock a buy for dividend portfolios2025 Price Targets & Verified Swing Trading Watchlists - mfd.ru
What are Ovid Therapeutics Inc.’s earnings expectationsWeekly Trend Report & Low Volatility Stock Suggestions - mfd.ru
What makes Ovid Therapeutics Inc. stock attractive todayJuly 2025 Technicals & Safe Capital Allocation Plans - mfd.ru
IPO Launch: Is Ovid Therapeutics Inc being accumulated by smart moneyJuly 2025 Reactions & Low Drawdown Trading Strategies - baoquankhu1.vn
Aug Retail: Can Silicom Ltd. navigate macro headwindsM&A Rumor & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Rating of “Buy” from Analysts - Defense World
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Risk Hedge: Is Ovid Therapeutics Inc stock risky to hold nowJuly 2025 Selloffs & Smart Allocation Stock Reports - baoquankhu1.vn
Ovid Therapeutics $OVID Position Cut by TLS Advisors LLC - MarketBeat
Is Ovid Therapeutics (OVID) One of the Best Fast Growing Penny Stocks to Buy According to Analysts? - Finviz
7 Best Fast Growing Penny Stocks to Buy According to Analysts - Insider Monkey
Both retail investors who control a good portion of Ovid Therapeutics Inc. (NASDAQ:OVID) along with institutions must be dismayed after last week's 11% decrease - simplywall.st
Ovid Therapeutics: Bullish Post-PIPE With 2 Differentiated CNS Moonshots - Seeking Alpha
Gains Report: Will Ionis Pharmaceuticals Inc benefit from sector rotation2025 Retail Activity & Growth Focused Investment Plans - baoquankhu1.vn
Does Ovid Therapeutics Inc. have declining or rising EPSWeekly Trend Report & Weekly Stock Breakout Alerts - mfd.ru
Why Ovid Therapeutics Inc. (1OT) stock stays on top picksTrading Volume Trends & Use Time as Your Investing Ally - bollywoodhelpline.com
Investment Recap: Will Ovid Therapeutics Inc announce a stock splitEntry Point & Expert Curated Trade Ideas - baoquankhu1.vn
What is the target price for Ovid Therapeutics Inc. stockQuarterly Trade Summary & Weekly Top Gainers Alerts - bollywoodhelpline.com
Finanzdaten der Ovid Therapeutics Inc-Aktie (OVID)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ovid Therapeutics Inc-Aktie (OVID) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Rona Jeffrey A | CBFO |
Feb 23 '26 |
Sale |
1.45 |
8,541 |
12,384 |
88,188 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):